Identification of 1-furan-2-yl-3-pyridin-2-yl-propenone, an anti-inflammatory agent, and its metabolites in rat liver subcellular fractions

Archives of Pharmacal Research

Volumn 29, Issue 11, 2006, Pages 984-989

  Sang, Kyu Lee ^a   Tae, Won Jeon ^a   Basnet, Arjun ^a   Hye, Gwang Jeong ^b   Eung, Seok Lee ^a   Tae, Cheon Jeong ^a  

^a Yeungnam University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

1 Furan 2 yl 3 pyridin 2 yl propenone; LC ESI MS; Metabolite; Reduction

Indexed keywords

EID: 33845367242     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02969282     Document Type: Article

References (11)

1. Clement, B., Demesmaeker, M., and Linne, S., Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolites: characterization of the two reactions and genotoxic potential of guanoxabenz. Chem. Res. Toxicol., 9, 682-688 (1996).
2. Jahng, Y., Zhao, L. X., Moon, Y.S., Basnet, A., Kim, E. K., Chang, H. W., Ju, H. K., Jeong, T. C., and Lee, E. S., Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activities. Bioorg. Med. Chem. Lett., 24, 2559-2562 (2004).
3. Lee, E. S., Ju, H. K., Moon, T. C., Lee, E., Jahng, Y., Lee, S. H., Son, J. K., Baek, S. H., and Chang, H. W., Inhibition of nitric oxide and tumor necrosis factor-α production by propenone compound through blockade of nuclear factor-kB activation in cultured murine macrophages. Biol. Pharm. Bull., 27, 617-620 (2004).
4. Lee, E. S., Park, B. C., Paek, S. H., Lee, Y. S., Basnet, A., Jin, D. Q., Choi, H. G., Yong, C. S., and Kim, J. A., Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-yl-propenone with gastric ulcer sparing effect. Biol. Pharm. Bull., 29, 361-364 (2006).
5. Lowry, O. H., Rosenbrough, N. J., Farr, A. L., and Randall, R. J., Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275 (1951).
6. Maser, E., Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. Biochem. Pharmacol., 49, 421-440 (1995).
7. Maser, E., 11β-Hydroxysteroid dehydrogenase acts as carbonyl reductase in microsomal phase 1 drug metabolism. Exp. Toxic. Pathol., 48, 266-273 (1996).
8. Maser, E., Friebertshäuser, J., and Völker, B., Purification, characterization and NNK carbonyl reductase activities of 11β- hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem-Biol. Interact., 143-144, 435-448 (2003).
9. Mertens, R. and Liese, A., Biotechnological applications of hydrogenase. Curr. Opin. Biotechnol., 15, 343-348 (2004).
10. Oppermann, U. C. T. and Maser, E., Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenase in xenobiotic phase I reactions. Toxicology, 144, 71-81 (2000).
11. Oppermann, U. C. T., Möbus, E., Nagal, G., and Maser, E., Heterogeneity of 11β-hydroxysteroid dehydrogenase type 1/microsomal carbonyl reductase (11β-HSD/CR) in guinea pig tissues. Purification of the liver form suggests modification in the cosubstrate binding site. Toxicology, 144, 63-69 (2000).